XNAS
AUPH
Market cap2.09bUSD
Oct 08, Last price
16.22USD
1D
1.31%
1Q
2.79%
Jan 2017
672.38%
IPO
305.50%
Name
Aurinia Pharmaceuticals Inc
Chart & performance
P/E
7.26
P/S
7.37
EPS
2.23
Div yield, %
—
Shrs. gr., 5y
3.20%
Rev. gr., 5y
41.38%
Revenues
283m
+20.38%
Net income
287m
+4,893.08%
CFO
136m
+205.62%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Aurinia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and marketing medical treatments. The company focuses on addressing various diseases across the United States and China. A key part of its pipeline involves voclosporin, an investigational compound being developed to treat conditions such as lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia's primary operations are based out of Victoria, Canada.
Key people
Chief Executive Officer, Director · since 2019
Robert B. Huizinga
Executive Vice President - Corporate Development · since 2017
Neil Solomons
Chief Marketing Officer · since 2013
Cara Felish
Vice President of Commercial Operations · since 2020
Fran Lynch
Vice President of Sales · since 2020
Lead Independent Director · since 2017
Daniel Billen
Director · since 2019
Director · since 2018
David Jayne
Independent Director · since 2015
Dennis Bourgeault
Chief Financial Officer, Corporate Secretary · since 2011
Headquarters & legal address
Suite 1203-4464 Markham Street
Victoria, BC V8Z 7X8
CA
Victoria, BC V8Z 7X8
CA
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||